FEMALE HORMONE REPLACEMENT

Testosterone improves sexual desire and sex

Home
HRT the smart choice for post menopausal women
10 reasons for HRT
Mechanism for hormone heart protection, endothelial cells
Estrogen lowers breast cancer death rate
Breast Cancer Survival up with subsequent HRT
Estradiol with progesterone, natural HRT
Estradiol longevity and cardiovascular disease
Taxoxifen is not worth side effects
Estrogens provents hardening of the arteries thus cardiovascular disease
Setting the record straight with journal articles on HRT
HRT for Postmenopausal Women, and PhARMA Profits First
More Setting the Record Straight
HRT Studies, much fewer heart attacks, etc.
Breast-Firmer-HRT
Cholesterol profile improved by Estradiol
Cognitive functions improved
Increased libido (sex drive)
More More setting the record right
healther skin with HRT
Bioidentical Hormone therapy advice
HRT benefits journals
Choice of progestagen component in HRT affects incidence of Breast cancer
HRT & Heart Benefits--etc.
22% muscle loss prevented with testosterone
Arthritis effective treatment HRT
Testosterone, Sex Drive, Feeling Better, etc--Mayo Clinic
Testosterone increases sexual drive
Testosterone improves sexual desire and sex
FDA Article on Menopause and HRT
Bioidentical Hormone therapy advice
Prempro settlement $330M
alcohol and higher estradiol and testosterone levels in postmenopausal women

Of the studies on women given testosterone, most are on those with surgically induced menopause, and they have consistently found that at the 300 micrograms dose of the patch a very significant increase in sexual desire and satisfying sex, as well as increased feeling of well-being.  Moreover there are no significant side effects, except for one study which reported more hair, 6.8% of women on testosterone versus placebo a self-reporting of greater hair growth. Self-reporting is the least reliable method of gathering data, since it is influenced by the woman’s beliefs.  The study below reported a two-fold increase in sexual desire and satisfying sex.

 

Other studies have shown assorted health benefits, comparable to that of estrogen, accept for effect testosterone isn’t cardio-vascular protective.  However, it does improve, unlike estrogen, the muscle tone and strength, but doesn’t build at this low dose unfeminine muscle mass.  Testosterone is well tolerated by women.  It has been for years used with estradiol in hormone replacement therapy. 

 

Arch Intern Med. 2005;165:1582-1589.  http://archinte.ama-assn.org/cgi/content/abstract/165/14/1582

 

Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

A Randomized, Placebo-Controlled Trial

Background  Oophorectomy reduces serum testosterone levels. We studied the efficacy and safety of transdermal testosterone in treating hypoactive sexual desire disorder in surgically menopausal women.

Methods  A 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted in women (aged 24-70 years) who developed distressful low sexual desire after bilateral salpingo-oophorectomy and hysterectomy and who were receiving oral estrogen therapy. Women were randomized to receive placebo (n = 119) or testosterone patches in dosages of 150 g/d (n = 107), 300 g/d (n = 110), or 450 g/d (n = 111) twice weekly for 24 weeks. Sexual desire and frequency of satisfying sexual activity wereprimary efficacy outcome measures.

Results  Of the 447 women randomized, 318 (71%) completed the trial. Compared with placebo, women receiving the 300-g/d testosterone patch had significantly greater increases from baseline in sexual desire (67% vs 48%P = .05) and in frequency of satisfying sexual activity (79% vs 43%P = .049). The 150-g/d group showed no evidence of a treatment effect. The 450-g/d group also was not statistically different from the 300-g/d or placebo groups. Marginally significant linear dose-response trends were observed for total satisfying sexual activity and sexual desire at 24 weeks (P = .06 and .06, respectively). Adverse events occurred with similar frequency in both groups; no serious safety concerns were observed.

Conclusions  The 300-g/d testosterone patch increased sexual desire and frequency of satisfying sexual activity and was well tolerated in women who developed hypoactive sexual desire disorder after surgical menopause.

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

This study like the one above (and others) have found increased sexual desire, satisfying sex, and increased feeling of well-being. Other studies support this result including a number in which for HRT testosterone had been used in women as a substitute for progesterone. 

http://www.regulabuerki.ch/files/pdf/en/Transdermal Testosterone Treatment 

Transdermal Testosterone Treatment in Women with Impaired Sexual Function after Oophorectomy --New England Journal of Medicine,343:682-688 Sept 7, 2000

Background

The ovaries provide approximately half the circulating testosterone in premenopausal women. After bilateral oophorectomy, many women report impaired sexual functioning despite estrogen replacement. We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced menopause.

Methods

Seventy-five women, 31 to 56 years old, who had undergone oophorectomy and hysterectomy received conjugated equine estrogens at least 0.625 mg per day orally (Prempo, an atypical HRT which is by far the worst--jk) and, in random order, placebo, 150 μg of testosterone, and 300 μg of testosterone per day transdermally for 12 weeks each. Outcome measures included scores on the Brief Index of Sexual Functioning for Women, the Psychological General Well-Being Index, and a sexual-function diary completed over the telephone.  {Details from full article at bottom}. 

Results

The mean (SD) serum free testosterone concentration increased from 1.20.8 pg per milliliter (4.22.8 pmol per liter) during placebo treatment to 3.92.4 pg per milliliter (13.58.3 pmol per liter) and 5.94.8 pg per milliliter (20.516.6 pmol per liter) during treatment with 150 and 300 μg of testosterone per day, respectively (normal range, 1.3 to 6.8 pg per milliliter [4.5 to 23.6 pmol per liter]). Despite an appreciable placebo response, the higher testosterone dose resulted in further increases in scores for frequency of sexual activity and pleasure–orgasm in the Brief Index of Sexual Functioning for Women (P=0.03 for both comparisons with placebo). At the higher dose, the percentages of women who had sexual fantasies, masturbated, or engaged in sexual intercourse at least once a week increased two to three times from base line. The positive-well-being, depressed-mood, and composite scores of the Psychological General Well-Being Index also improved at the higher dose (P=0.04, P=0.03, and P=0.04, respectively, for the comparison with placebo), but the scores on the telephone-based diary did not increase significantly.

Conclusions

In women who have undergone oophorectomy and hysterectomy, were given oral Prempo and transdermal testosterone improves sexual function and psychological well-being.

^^^^^^^^^

From complete article at http://www.regulabuerki.ch/files/pdf/en/Transdermal%20Testosterone%20Treatment%20in%20Women.pdf

All 75 women had undergone bilateral salpingo-ophorectomy and hysterectomy before menopause at least 1 year but not more than 10 years.  All had undergone bilateral salpingo-oophorectomy and hysterectomy.  METHOD:  After screening and a 4-week base-line period, the women began three consecutive 12-week treatment periods during which they received, in random order, the following regimens of transdermal patches applied twice weekly: two placebo patches (no active drug), one active and one placebo patch (nominal dose of testosterone, 150 μg per day), and two active patches (nominal dose of testosterone, 300 μg per day) (where the nominal dose is the amount of drug that will be absorbed by a person with average skin permeability during the application time). Neither the women nor the investigators knew the contents of the patches. Throughout the study, including the base-line period, the women received concomitant oral conjugated equine estrogens at their prestudy doses.  The identical-appearing experimental patches (Watson Laboratories, Salt Lake City) were applied on the abdomen and were changed every three to four days. 16,17  As a condition of enrollment, all the women in our study wanted their sex lives to be more active or satisfying.   In addition, the visible presence of the transdermal patches (active or placebo) might have been a stimulus to some women or their partners to increase sexual activity. Because the younger women had been in shorter relationships than the older women (13 vs. 18 years), they may have felt greater pressure to improve their sexual functioning. RESULTS  With the testosterone dose of 300 μg per day, the increases in scores for frequency of sexual activity and pleasure–orgasm were significantly greater than those with placebo…. The percentage of women who reported having sexual fantasies at least once a week was 12 percent at base line, 10 percent during placebo treatment, 18 percent during treatment with 150 μg of testosterone per day, and 24 percent during treatment with 300 μg of testosterone per day…. The percentage of women who reported having sexual fantasies at least once a week was 12 percent at base line, 10 percent during placebo treatment, 18 percent during treatment with 150 μg of testosterone per day, and 24 percent during treatment with 300 μg of testosterone per day.  In addition, the visible presence of the transdermal patches (active or placebo) might have been a stimulus to some women or their partners to increase sexual activity. Because the younger women had been in shorter relationships than the older women (13 vs. 18 years), they may have felt greater pressure to improve their sexual functioning.  Treatment with the higher

dose of testosterone improved sexual function and psychological well-being substantially more than placebo

treatment.

 

 

Enter supporting content here

Teddy Roosevelt's advised that, "We must drive the special interests out of politics. The citizens of the United States must effectively control the mighty commercial forces which they have themselves called into being. There can be no effective control of corporations while their political activity remains."